相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men
Takashi Matsumoto et al.
INTERNATIONAL JOURNAL OF UROLOGY (2021)
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors
Apostolia-Maria Tsimberidou et al.
ONCOLOGIST (2021)
Genomic landscape of platinum resistant and sensitive testicular cancers
Chey Loveday et al.
NATURE COMMUNICATIONS (2020)
Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy
Andrea Necchi et al.
EUROPEAN UROLOGY FOCUS (2020)
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
Andrea Necchi et al.
EUROPEAN UROLOGY (2019)
Phase II study of avelumab in multiple relapsed/refractory germ cell cancer
M. Mego et al.
INVESTIGATIONAL NEW DRUGS (2019)
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
Ari Vanderwalde et al.
CANCER MEDICINE (2018)
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Xian Shen et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
N. Adra et al.
ANNALS OF ONCOLOGY (2018)
Platinum-refractory germ cell tumors: an update on current treatment options and developments
Christoph Oing et al.
WORLD JOURNAL OF UROLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor
Ethan A. Chi et al.
CLINICAL GENITOURINARY CANCER (2017)
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
Z. Cierna et al.
ANNALS OF ONCOLOGY (2016)
Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors
S. Zschabitz et al.
ANNALS OF ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Absence of microsatellite instability and BRAF (V600E) mutation in testicular germ cell tumors
F. M. Carcano et al.
ANDROLOGY (2016)
Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors
Shalin Shah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Frequent PD-L1 expression in testicular germ cell tumors
C. D. Fankhauser et al.
BRITISH JOURNAL OF CANCER (2015)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Luisa Carbognin et al.
PLOS ONE (2015)
Testicular Cancer - Discoveries and Updates
Nasser H. Hanna et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design
Darren R. Feldman et al.
CANCER (2012)
Long-Term Survival After Treatment with Gemcitabine and Oxaliplatin With and Without Paclitaxel Plus Secondary Surgery in Patients with Cisplatin-Refractory and/or Multiply Relapsed Germ Cell Tumors
Karin Oechsle et al.
EUROPEAN UROLOGY (2011)
TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis
Darren R. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors
Lawrence H. Einhorn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
分享论文
